The drug-elicitable alternative splicing module for tunable vector expression in the heart
RNA-seq (gene expression) · human · 36 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 36 samples: 10 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- The drug-elicitable alternative splicing module for tunable vector expression in the heartNature cardiovascular research · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE270445_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1126649 and SRA study SRP515245. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 3 samples read as cases, 10 as controls.
How we read this: 10 replicated groups read from 36 sample titles; they account for 36 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8343059 WT, risdiplam, 1 day post risdiplam, rep1 WT, risdiplam, 1 day po…
- GSM8343060 WT, risdiplam, 1 day post risdiplam, rep2 WT, risdiplam, 1 day po…
- GSM8343061 WT, risdiplam, 1 day post risdiplam, rep3 WT, risdiplam, 1 day po…
- GSM8343062 WT, risdiplam, 1 day post risdiplam, rep4 WT, risdiplam, 1 day po…
- GSM8343063 WT, risdiplam, 1 day post risdiplam, rep5 WT, risdiplam, 1 day po…
- GSM8343064 WT, solvent, 1 day post solvent, rep1 WT, solvent, 1 day post…
- GSM8343065 WT, solvent, 1 day post solvent, rep2 WT, solvent, 1 day post…
- GSM8343066 WT, solvent, 1 day post solvent, rep3 WT, solvent, 1 day post…
- GSM8343067 WT, solvent, 1 day post solvent, rep4 WT, solvent, 1 day post…
- GSM8343068 WT, solvent, 1 day post solvent, rep5 WT, solvent, 1 day post…
- GSM8343069 AAV-injection, solvent, 1 day post solvent, rep1 AAV-injection, solvent,…
- GSM8343070 AAV-injection, solvent, 1 day post solvent, rep2 AAV-injection, solvent,…
- GSM8343071 AAV-injection, solvent, 1 day post solvent, rep3 AAV-injection, solvent,…
- GSM8343072 AAV-injection, risdiplam,1 day post risdiplam, rep1 AAV-injection, risdipla…
- GSM8343073 AAV-injection, risdiplam,1 day post risdiplam, rep2 AAV-injection, risdipla…
- GSM8343074 AAV-injection, risdiplam,1 day post risdiplam, rep3 AAV-injection, risdipla…
- GSM8343075 AAV-injection, solvent, 11 days post solvent, rep1 AAV-injection, solvent,…
- GSM8343076 AAV-injection, solvent, 11 days post solvent, rep2 AAV-injection, solvent,…
- GSM8343077 AAV-injection, solvent, 11 days post solvent, rep3 AAV-injection, solvent,…
- GSM8343078 AAV-injection, risdiplam,11 days post risdiplam, rep1 AAV-injection, risdipla…
- GSM8343079 AAV-injection, risdiplam,11 days post risdiplam, rep2 AAV-injection, risdipla…
- GSM8343080 AAV-injection, risdiplam,11 days post risdiplam, rep3 AAV-injection, risdipla…
- GSM8522330 6-8h plasmid-transfection, 24h risdiplam-treated, rep1 6-8h plasmid-transfecti…
- GSM8522331 6-8h plasmid-transfection, 24h risdiplam-treated, rep2 6-8h plasmid-transfecti…
- GSM8522332 6-8h plasmid-transfection, 24h risdiplam-treated, rep3 6-8h plasmid-transfecti…
- GSM8522333 6-8h plasmid-transfection, 24h DMSO-treated, rep1 6-8h plasmid-transfecti…
- GSM8522334 6-8h plasmid-transfection, 24h DMSO-treated, rep2 6-8h plasmid-transfecti…
- GSM8522335 6-8h plasmid-transfection, 24h DMSO-treated, rep3 6-8h plasmid-transfecti…
- GSM8522336 AAV-injection, risdiplam, 30 day post risdiplam, rep1 AAV-injection, risdipla…
- GSM8522337 AAV-injection, solvent, 30 day post solvent, rep1 AAV-injection, solvent,…
- GSM8522338 AAV-injection, risdiplam, 30 day post risdiplam, rep2 AAV-injection, risdipla…
- GSM8522339 AAV-injection, solvent, 30 day post solvent, rep2 AAV-injection, solvent,…
- GSM8522340 AAV-injection, solvent, 30 day post solvent, rep3 AAV-injection, solvent,…
- GSM8522341 AAV-injection, risdiplam, 30 day post risdiplam, rep3 AAV-injection, risdipla…
- GSM8522342 AAV-injection, solvent, 30 day post solvent, rep4 AAV-injection, solvent,…
- GSM8522343 AAV-injection, risdiplam, 30 day post risdiplam, rep4 AAV-injection, risdipla…
- GSE255769 Polyamine-dependent metabolic shielding regulates alternative splicing 144 samples shares alternative, splicing
- GSE286557 Nitric oxide drives proteomic diversity through alternative splicing 44 samples shares alternative, splicing
- GSE324908 Alternative splicing-triggered mRNA decay informs splice-switching targets for neurodevelopmental disorders 14 samples shares alternative, splicing
- GSE294247 The PRMT5-splicing axis is a critical oncogenic vulnerability that regulates detained intron splicing 110 samples shares splicing
- GSE277551 HNF1A regulates a β-cell RNA splicing program that is disrupted in type 2 diabetes [RNA-seq] 17 samples shares splicing
- GSE225396 ZRSR2-loss causes aberrant splicing in a JAK2V617F-driven myeloproliferative neoplasm but is not sufficient to drive disease progression 17 samples shares splicing
- GSE239745 Mis-splicing Drives Loss of Function of p53E224D Point Mutation 15 samples shares splicing
- GSE274590 Snord67 promotes breast cancer metastasis by guiding U6 modification and modulating the splicing landscape 15 samples shares splicing
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.